Galectin-1 Expression in CD8


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
06 2021
Historique:
received: 26 03 2020
revised: 05 10 2020
accepted: 14 10 2020
pubmed: 13 11 2020
medline: 20 11 2021
entrez: 12 11 2020
Statut: ppublish

Résumé

Allergic contact dermatitis, also known as contact hypersensitivity, is a frequent T-cell‒mediated inflammatory skin disease characterized by red, itchy, swollen, and cracked skin. It is caused by the direct contact with an allergen and/or irritant hapten. Galectin-1 (Gal-1) is a β-galactoside‒binding lectin, which is highly expressed in several types of immune cells. The role of endogenous Gal-1 in contact hypersensitivity is not known. We found that Gal-1‒deficient mice display more sustained and prolonged skin inflammation than wild-type mice after oxazolone treatment. Gal-1‒deficient mice have increased CD8

Identifiants

pubmed: 33181141
pii: S0022-202X(20)32281-8
doi: 10.1016/j.jid.2020.10.020
pii:
doi:

Substances chimiques

Galectin 1 0
Lgals1 protein, mouse 0
Oxazolone 15646-46-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1522-1532.e3

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Raquel Castillo-González (R)

Immunology Service, Hospital de la Princesa, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Madrid, Spain; Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; Department of Intercellular Communication in the Inflammatory Response, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.

Danay Cibrian (D)

Immunology Service, Hospital de la Princesa, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Madrid, Spain; Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; Department of Intercellular Communication in the Inflammatory Response, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; CIBER de Enfermedades Cardiovasculares, Carlos III Health Institute, Madrid, Spain.

Nieves Fernández-Gallego (N)

Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; Department of Intercellular Communication in the Inflammatory Response, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.

Marta Ramírez-Huesca (M)

Department of Intercellular Communication in the Inflammatory Response, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.

María Laura Saiz (ML)

Immunology Service, Hospital de la Princesa, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Madrid, Spain; Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.

María N Navarro (MN)

Department of Immune System Development and Function, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Madrid, Spain.

Manuel Fresno (M)

Department of Immune System Development and Function, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Madrid, Spain.

Hortensia de la Fuente (H)

Immunology Service, Hospital de la Princesa, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Madrid, Spain; Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; Department of Intercellular Communication in the Inflammatory Response, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; CIBER de Enfermedades Cardiovasculares, Carlos III Health Institute, Madrid, Spain.

Francisco Sánchez-Madrid (F)

Immunology Service, Hospital de la Princesa, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Madrid, Spain; Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; Department of Intercellular Communication in the Inflammatory Response, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; CIBER de Enfermedades Cardiovasculares, Carlos III Health Institute, Madrid, Spain. Electronic address: fsmadrid@salud.madrid.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH